← Back to Clinical Trials
Recruiting NCT07179887

NCT07179887 Remote Ischaemic Conditioning in the Older Person and Effects on Dynamic Cerebral Autoregulation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07179887
Status Recruiting
Phase
Sponsor University of Nottingham
Condition Cerebral Autoregulation
Study Type INTERVENTIONAL
Enrollment 45 participants
Start Date 2025-08-27
Primary Completion 2027-09-01

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Remote Ischaemic ConditioningSham Remote Ischaemic Conditioning

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 45 participants in total. It began in 2025-08-27 with a primary completion date of 2027-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Remote Ischaemic Conditioning (RIC) is the process of inducing short periods of ischaemia in a limb with the aim of improving vascular health systemically. Recent findings have demonsatrated efficacy in a variety of clinical settings. However, the ideal protocol of RIC \[dose\] is unknown. Dynamic Cerebral Autoregulation (dCA) has been shown to increase in response to RIC. The goal of this trial is to study whether an increase in RIC protocol intensity results in a larger effect on biomarkers of vascular health such as dCA. Participants shall: Receive RIC daily, RIC thrice weekly or sham RIC thrice weekly for 6 weeks Visit the School of Medicine at baseline and at 6 weeks for measurement of biomarkers of vascular health including blood pressure, indices od dCA and blood plasma samples

Eligibility Criteria

Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study * Participant aged 65 - 85 * Participant is able to perform RIC independently at home Exclusion Criteria: * Active cardiovascular or cerebrovascular disease (acute event within the last 12 months) * Atrial fibrillation or other significant arrhythmias * Peripheral Vascular Disease * Haemostatic disorders * Soft tissue injury or fracture to the upper limb * Pregnant or breast feeding * History or current psychiatric illness * History or current neurological condition (e.g. epilepsy) * Inability to identify temporal window for transcranial doppler ultrasound at screening visit * Any condition or presentation under current investigation that is deemed by the study clinician to exclude the participant from the study. * Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance

Contact & Investigator

Central Contact

Harry Keevil, MB BChir

✉ harry.keevil@nottingham.ac.uk

📞 +441332 724676

Principal Investigator

Tim England, MBChB PhD

PRINCIPAL INVESTIGATOR

University of Nottingham

Frequently Asked Questions

Who can join the NCT07179887 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, up to 85 Years, studying Cerebral Autoregulation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07179887 currently recruiting?

Yes, NCT07179887 is actively recruiting participants. Contact the research team at harry.keevil@nottingham.ac.uk for enrollment information.

Where is the NCT07179887 trial being conducted?

This trial is being conducted at Derby, United Kingdom.

Who is sponsoring the NCT07179887 clinical trial?

NCT07179887 is sponsored by University of Nottingham. The principal investigator is Tim England, MBChB PhD at University of Nottingham. The trial plans to enroll 45 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology